Phase 2 Prostate Cancer Trial, Recruiting NCT06409910 Sponsor: University Health Network, Toronto Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06409910
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You are able to understand and agree to take part in the study (give informed consent)
  • You have been diagnosed with prostate cancer (specifically a type called adenocarcinoma, confirmed by a tissue test)
  • You are generally well enough to carry out light activity and care for yourself (confirm with trial site)
  • You had surgery to remove your prostate (radical prostatectomy) more than 6 months before starting radiation treatment
  • You are already planned to receive radiation treatment after your prostate surgery

Who may not be able to join:

  • You have previously had radiation treatment to your pelvis area
  • You have a medical reason why radiation treatment would not be safe for you
  • Scans done as part of your regular care have shown that the cancer has spread to other parts of your body (metastases)
  • Scans have shown visible signs of cancer remaining in the area where your prostate was removed, or in nearby lymph nodes in the pelvis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
26 November 2024
Est. completion
1 November 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Rates of Acute Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov